Eli Lilly shares initially experienced pre-market volatility but recovered strongly, closing up 1.14% at $1,053.42, as investors focused on the company's defining year ahead and robust revenue projections.
- Analysts project revenue reaching $94.3 billion by 2027, which would be more than double 2024 levels.
- Key catalysts include the expected Q2 approval of the oral obesity drug, Orforglipron.
- The company anticipates Q1 head-to-head data comparing Novo's CagriSema against Lilly's Tirzepatide, amid intensifying global pricing competition and regulatory complexity.